Hepatitis C cross-genotype immunity and implications for vaccine development

about

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.

P2860

Q55303632-A7496E13-ED53-4DDA-8D19-726D756EB9C3

P2860

Hepatitis C cross-genotype immunity and implications for vaccine development

Item

http://www.wikidata.org/entity/Q42364607

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hepatitis C cross-genotype immunity and implications for vaccine development

@en

Hepatitis C cross-genotype immunity and implications for vaccine development

@nl

type

Item

label

Hepatitis C cross-genotype immunity and implications for vaccine development

@en

Hepatitis C cross-genotype immunity and implications for vaccine development

@nl

prefLabel

Hepatitis C cross-genotype immunity and implications for vaccine development

@en

Hepatitis C cross-genotype immunity and implications for vaccine development

@nl

P1476

Hepatitis C cross-genotype immunity and implications for vaccine development

@en

P2093

Jason Wong

http://www.w3.org/2001/XMLSchema#string

Jean Shoveller

http://www.w3.org/2001/XMLSchema#string

Mark Gilbert

http://www.w3.org/2001/XMLSchema#string

Paul Gustafson

http://www.w3.org/2001/XMLSchema#string

The BC-HTC Team

http://www.w3.org/2001/XMLSchema#string

P2860

Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users

Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection

Protective immunity against hepatitis C: many shades of gray.

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.

Signatures of protective memory immune responses during hepatitis C virus reinfection.

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Response-guided telaprevir combination treatment for hepatitis C virus infection

Cross-genotype immunity to hepatitis C virus.

P2888

s41598-017-10190-8

P304

12326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-10190-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28951612

http://www.w3.org/2001/XMLSchema#string

P932

5615075

http://www.w3.org/2001/XMLSchema#string

Hepatitis C cross-genotype immunity and implications for vaccine development

about

P2860

P2860

Hepatitis C cross-genotype immunity and implications for vaccine development

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932